CONSHOHOCKEN, Pa.--CardioNet, Inc. (NASDAQ: BEAT) announced today that the 300,000th patient has been monitored with the Company’s Mobile Cardiac Outpatient Telemetry (MCOT) service. MCOT is the first system to provide real-time wireless ECG monitoring and 24/7/365 analysis and response.
Randy Thurman, CardioNet Chairman, President and CEO, commented, “With 300,000 patients having now benefited from our MCOT service, it is evident that an increasing number of physicians view real-time, 24/7 monitoring of cardiac arrhythmias as crucial to identifying and preventing life-threatening cardiac-related events such as stroke. The continued availability and adoption of MCOT also brings value to the entire healthcare continuum as it enables physicians to manage arrhythmias before they manifest into more severe conditions that demand significantly greater costs and resources to treat.”
MCOT offers several advantages to physicians, payors, and patients, including: real-time, continuous ECG data analysis; customizable concise reporting to enhance diagnosis and treatment decisions; increased patient compliance through technology and reduced interaction; reflection of real-life cardiac activity; detection of arrhythmias where symptoms are not experienced; minimization of data artifacts or “noise”; two-way wireless capabilities for transmission; ability to associate symptoms and activity with ECG event; remote programming and data retrieval; and the ability to tailor the system to physicians’ needs. Due to these advantages, CardioNet’s MCOT continues to increase its significant leadership position in the mobile cardiac telemetry market.
Dr. Paul Schweitzer, Director of Cardiac Arrhythmia Service at Beth Israel Medical Center and Asst. Chief of Cardiology at Albert Einstein College of Medicine in New York City treated the 300,000th MCOT patient.
“The ability to immediately detect a cardiac arrhythmia and then closely monitor the patient for repeat occurrences provides numerous treatment advantages, not the least of which is giving the cardiologist an opportunity to address the condition before it causes a more severe, potentially irreparable outcome,” said Dr. Schweitzer. “Through its beat-by-beat wireless monitoring, MCOT provides assurance that these sometimes difficult to detect irregularities will be diagnosed in a manner that allows the physician to understand the root cause and prescribe a course of action for the patient’s individual needs.”
About CardioNet
CardioNet is the leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. CardioNet's initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry™ (MCOT™). More information can be found at http://www.cardionet.com.
Forward Looking Statements
This press release includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company's future. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, changes to reimbursement levels for our products, the continued consolidation of payors, acceptance of our new products and services and patent protection and litigation. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
